Document is current
Any future updates will be listed below
-
Authors
Kobayashi, Takahiro https://orcid.org/0000-0002-8058-7301
Sato, Honami
Miura, Masatomo
Fukushi, Yayoi
Kuroki, Wataru
Ito, Fumiko
Teshima, Kazuaki
Watanabe, Atsushi
Fujishima, Naohito
Kobayashi, Isuzu
Kameoka, Yoshihiro
Takahashi, Naoto
-
Funding
Funding for this research was provided by:
Otsuka Pharmaceutical
Novartis Japan
Astellas Pharma
Asahikasei Pharma Japan
Ono Pharmaceutical
- License Information
-
More Information
Article History
Received: 22 January 2024
Accepted: 1 May 2024
First Online: 23 May 2024
Declarations
:
: The multicenter prospective observational study was conducted in Akita prefecture, Japan. This study enrolled patients with AML who were judged ineligible for intensive chemotherapy by the attending physician. This study was conducted in accordance with the 1964 Helsinki Declaration and approved by the Ethics Committee of Akita University (August 6, 2021/No. 2696). Written informed consent was obtained from all participants before enrollment.
: Naoto Takahashi received honoraria from Otsuka, Novartis, and received research funding from Otsuka, Novartis, Astellas, Asahikasei Pharma, and Ono Pharmaceutical.
